Emily Salmini

[Scientific Reports] The authors conducted a thorough examination of utrophin (UTRN) using both bioinformatic and in vitro experiments. UTRN expression decreased in breast cancer compared to standard samples, and high UTRN expression correlated with better prognosis.

[EMBO Journal] Scientists reported that nuclear phosphoinositides functioned as cofactors that mediated the binding of yes-associated protein 1 (YAP)/TAZ to TEA domain (TEAD) family transcription factors.

[EMBO Journal] Investigators reported the physical, biochemical, and genomic differences between T47D breast cancer cells cultured in 2D and as 3D spheroids.

[Incyte Corporation] Incyte and China Medical System Holdings Limited (CMS) announced their collaboration and license agreement for the development and commercialization of povorcitinib, a selective oral JAK1 inhibitor. CMS will receive a non-exclusive license to manufacture povorcitinib in autoimmune and inflammatory dermatologic diseases, including non-segmental vitiligo, hidradenitis suppurativa, prurigo nodularis, and chronic spontaneous urticaria.

[Cell Death Discovery] Researchers showed that steroid receptor RNA activator-like non-coding RNA (SLNCR1) was significantly up-regulated in human malignant melanoma tissues and cell lines and functioned as an oncogene. Silencing of SLNCR1 suppressed melanoma cell proliferation, migration, invasion, and inhibited tumorigenesis in a mouse xenograft model.

[Scientific Reports] Analogues of echinomycin, a cyclic peptide natural product with potent toxicity to several human cancer cell lines, were synthesized, and their biological activities against human colon cancer cells were investigated.